GPR43 potentiates β-cell function in obesity

JC McNelis, YS Lee, R Mayoral, R van der Kant… - Diabetes, 2015 - Am Diabetes Assoc
JC McNelis, YS Lee, R Mayoral, R van der Kant, AMF Johnson, J Wollam, JM Olefsky
Diabetes, 2015Am Diabetes Assoc
The intestinal microbiome can regulate host energy homeostasis and the development of
metabolic disease. Here we identify GPR43, a receptor for bacterially produced short-chain
fatty acids (SCFAs), as a modulator of microbiota-host interaction. β-Cell expression of
GPR43 and serum levels of acetate, an endogenous SCFA, are increased with a high-fat
diet (HFD). HFD-fed GPR43 knockout (KO) mice develop glucose intolerance due to a defect
in insulin secretion. In vitro treatment of isolated murine islets, human islets, and Min6 cells …
The intestinal microbiome can regulate host energy homeostasis and the development of metabolic disease. Here we identify GPR43, a receptor for bacterially produced short-chain fatty acids (SCFAs), as a modulator of microbiota-host interaction. β-Cell expression of GPR43 and serum levels of acetate, an endogenous SCFA, are increased with a high-fat diet (HFD). HFD-fed GPR43 knockout (KO) mice develop glucose intolerance due to a defect in insulin secretion. In vitro treatment of isolated murine islets, human islets, and Min6 cells with (S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide (PA), a specific agonist of GPR43, increased intracellular inositol triphosphate and Ca2+ levels, and potentiated insulin secretion in a GPR43-, Gαq-, and phospholipase C–dependent manner. In addition, KO mice fed an HFD displayed reduced β-cell mass and expression of differentiation genes, and the treatment of Min6 cells with PA increased β-cell proliferation and gene expression. Together these findings identify GPR43 as a potential target for therapeutic intervention.
Am Diabetes Assoc